Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Non-Current Assets (2016 - 2026)

Summit Therapeutics filings provide 13 years of Non-Current Assets readings, the most recent being $31.3 million for Q1 2026.

  • Quarterly Non-Current Assets rose 139.14% to $31.3 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $92.2 million through Mar 2026, up 82.55% year-over-year, with the annual reading at $30.9 million for FY2025, 161.48% up from the prior year.
  • Non-Current Assets hit $31.3 million in Q1 2026 for Summit Therapeutics, up from $30.9 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $31.3 million in Q1 2026 and bottomed at $6.9 million in Q1 2023.
  • Average Non-Current Assets over 5 years is $15.2 million, with a median of $13.5 million recorded in 2024.
  • The largest annual shift saw Non-Current Assets crashed 59.68% in 2023 before it skyrocketed 161.48% in 2025.
  • Summit Therapeutics' Non-Current Assets stood at $7.5 million in 2022, then skyrocketed by 77.53% to $13.2 million in 2023, then dropped by 10.78% to $11.8 million in 2024, then soared by 161.48% to $30.9 million in 2025, then increased by 1.22% to $31.3 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Non-Current Assets are $31.3 million (Q1 2026), $30.9 million (Q4 2025), and $15.3 million (Q3 2025).